Global iv iron market 2014 edition
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
157
On Slideshare
157
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
1
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Global IV Iron Drugs Market ----------------------------------------------------- 2014 View Report Details
  • 2. Executive Summary Iron is one of the most important nutritional requirements of the human body as it plays an important role in the managing many vital biological processes. These biological processes encompass synthesis of heme which forms the basis of hemoglobin; the oxygen- carrying protein of the blood; the formation of myoglobin, energy metabolism, neurotransmitter production, the formation of collagen and immune system function apart from others. An individual suffering from iron deficiency can maintain the requisite level of iron mainly through two types of supplements: oral iron supplements and intravenous iron supplements (IV). Treatment with oral iron supplements is simple, inexpensive and a relatively effective way of treating iron deficiency conditions; however, in many iron deficient conditions, oral iron is a less than the ideal treatment. Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous (IV) drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron. The key factors driving growth of the global IV iron industry include escalating number of dialysis and hypertension cases, ameliorating economic conditions, increasing global healthcare expenditures, and rising medicines expenditures. Some of the noteworthy trends and developments of this industry encompass novel product development, bundled payment systems and increasing penetration of genecology sector. However, the growth of this industrial sector is being hindered by stringent regulatory structures and adverse affects associated with the use of IV iron products. The report analyzes the global iron product industry along with an extensive coverage of global and the US IV iron market. The global IV iron market witnesses intense competition with numerous top notch players; such as Galenica Pharmaceuticals, Actavis Inc, AMAG Pharmaceuticals; operating in the marketplace along with small budding players. As a part of analysis of fierce competition prevailing in the industry product contention has been presented in the report. The company profiles of leading aforementioned players in the market are also incorporated in the report. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests. View Report Details
  • 3. Iron products are chiefly divided into two types: oral and intravenous and it is noteworthy that the global iron products market is dominated by oral products due to easy of usage. • After witnessing a mild decline in 2012 due to unfavorable exchange rates, the global iron product market was valued at US$.... billion at the end of 2013. This marked an incline of ….%, compared to US$.… billion during the previous year. In addition to this, the overall growth was noted at a noteworthy CAGR of ….% from US$.... billion in 2009 to US$..... billion in 2013. •Oral iron products held ….% share of the total revenue generated by the global iron products industry whist intravenous products accounted for remaining ….% share. • In terms of value, oral iron products contributed US$.... billion to the global iron product industry at the end of 2013. Intravenous iron products accounted for US$.... billion out of the aforementioned industry. Global Iron Products Value – by Segments (2013) Global Iron Products Market Share – by Segments (2013) Global Iron Products Market (2009-2013) Oral Intravenous 2009 2010 2011 2012 2013 US$Billion 1.41739663 1.02229597 Oral Intravenous US$Billion
  • 4. The key factors driving growth of the global IV iron industry include escalating number of dialysis and hypertension cases, increasing global healthcare expenditures, and rising medicines expenditures. • There has been a significant increase in the global consumption of iron replacement products worldwide. The global IV iron market was worth US$..... million in 2013, up by …..%, compared to US$.... million in 2012. The growth of global IV iron market was noted at a CAGR of ….% during the period spanning 2009 to 2013. • The IV iron market in the US has been steadily increasing over the past couple of years. The US IV iron market marked an incline of ….% to reach US$.... million at the end of 2013, compared to US$.... million in the prior year. The incline in the US marketplace was chiefly due to ameliorating economic conditions thereby fueling the spending power of individuals on healthcare. • The US non-dialysis IV iron replacement has been slowly but steadily increasing since 2011. On an estimated basis, the size of the total 2013 the US non-dialysis IV iron replacement therapy market was approximately ….. grams, which depicted an increase of …..% over 2012 when the size was ……. grams. US Non-Dialysis IV Iron Market (2011-2013) The US IV Iron Market Size (2009-2013) Global IV Iron Market (2009-2013) 2009 2010 2011 2012 2013 US$Million 2011 2012 2013 Grams 2009 2010 2011 2012 2013 US$Billion
  • 5. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries, apart from others.  It is anticipated that in 2013, Venofer Fresenius Kabi Branded Generic held …..% share of the totak IV Iron market in the US, followed by …..% share of Venofer Luitpold Inc Brand. Feraheme AMAG Pharm Branded Generic represented …..% share. Apart from the aforementioned products, other products which depicted a significant share on the US marketplace were Infed Watson Pharma Branded Generic, Ferrlecit Sanofi Aventis Branded Generic, depicting ….% share each, and Nulecit Watson Pharma Branded Generic, representing ….% share. As of first quarter of 2014, Venofer was the leading product in the US non-dialysis IV iron market with ….% share followed by Iron Dextran/Dexferrum with ….% share. Other leading products forming the US non-dialysis IV iron market encompass Feraheme, Ferric Gluconate, and Injectafer.  Intravenous iron therapies find maximum use in nephrology segment, as a high percentage of the patients suffering from chronic kidney diseases or CKD require them, owing to the low absorption of iron and decline in appetite due to kidney failure. In addition, patients who suffer from ESRD and undergo dialysis are the major consumers of IV iron products. This segment is expected to further benefit the global IV iron market in the coming years, chiefly due to an expected increase in the number of CKD and dialysis patients worldwide. All the factors mentioned above are certain to boost the performance of the global IV iron market, which is forecasted to reach US$...... million by the end of 2018 from US$..... million in 2013. During the five year period from 2013 to 2018, the global market for IV iron is expected to grow at a CAGR of …..%. Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa Venofer Fresenius Kabi Branded Generic Venofer Luitpold Pharm Inc. Brand Feraheme AMAG Pharm Branded Generic Infed Watson Pharma Branded Generic Ferrlecit Sanofi Aventis Branded Generic Nulecit Watson Pharma Branded Generic Others IV Iron Market Share in the US (2013E) 2009 2010 2011 2012 2013 2014F 2015F 2016F 2017F 2018F US$Million Global IV Iron Market Forecast (2009-2018F)
  • 6. Koncept Analytics CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com Contact Us: www.konceptanalytics.com Vikas Gupta BD Manager These are abridged and sanitized sample pages from the comprehensive report on the “ Global IV Iron Market Report”. To know more about this report or for any customized research requirement, please contact the following: View Report Details